Experimental vaccine targets Hard-to-Treat pancreatic cancer
NCT ID NCT00669734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a vaccine therapy given directly into the tumor along with a growth factor to boost the immune system in 18 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effects. While the approach aims to help the body fight the cancer, it is not a cure and ongoing treatment may be needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Exercise before and after pancreatic cancer surgery may speed recovery and chemotherapy start
- Could a simple blood test catch pancreatic cancer before It's too late?
- New drug combo aims to boost Chemotherapy's punch against pancreatic cancer
- New drug cocktail aims to shrink pancreatic tumors before surgery